Form 4: Nascent Biotech Director Douglas Karas Acquires 27,100 Shares

Director Douglas Karas acquired 27,100 shares of Nascent Biotech Inc. (NBIO) at a price of $0.1845 on March 31, 2024, as part of his employment contract.

Summary

• On March 31, 2024, Douglas Karas, a director of Nascent Biotech Inc. (NBIO), acquired 27,100 shares of common stock.
• The shares were acquired at a price of $0.1845 per share.
• This transaction increased Karas's direct ownership to 1,771,552 shares.
• The acquisition was part of Karas's employment contract with the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director acquiring shares as part of an employment contract. While insider buying is generally viewed positively, the context of an employment contract makes it less indicative of strong positive sentiment.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Key Dates

Keywords

Nascent Biotech Inc., NBIO, Douglas Karas, Director, Share Acquisition, Form 4, Beneficial Ownership, Common Stock, Employment Contract